Roche in antibiotics deal with Polyphor

Polyphor Ltd. (Allschwil, Switzerland) granted Roche (SIX:ROG; OTCQX:RHHBY) exclusive, worldwide rights to develop and commercialize POL7080, which is in Phase II testing to treat bacterial infections caused by Pseudomonas aeruginosa. Polyphor will receive CHF35 million ($38.3 million) up front and is eligible for up to CHF465 million ($509.2 million) in milestones, plus double-digit royalties. Polyphor has the option to co-promote an inhaled formulation of POL7080 in Europe. The compound is a synthetic cyclo-peptide antibiotic targeting the Pseudomonas LPS-assembly protein (OstA; LptD; Imp). ...